Somewhat Positive News Coverage Somewhat Unlikely to Impact Kala Pharmaceuticals (NASDAQ:KALA) Share Price

News articles about Kala Pharmaceuticals (NASDAQ:KALA) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.3817246107985 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

Kala Pharmaceuticals (KALA) traded up $1.75 during trading hours on Friday, hitting $15.60. The stock had a trading volume of 386,703 shares, compared to its average volume of 457,226. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals has a twelve month low of $11.81 and a twelve month high of $26.75.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.14). research analysts forecast that Kala Pharmaceuticals will post -2.22 earnings per share for the current year.

A number of brokerages recently commented on KALA. Zacks Investment Research downgraded Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Wedbush restated a “buy” rating and issued a $46.00 target price on shares of Kala Pharmaceuticals in a research report on Thursday, November 30th. BidaskClub upgraded Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 29th. JPMorgan Chase & Co. set a $35.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Kala Pharmaceuticals in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Kala Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $36.80.

In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc bought 170,338 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was acquired at an average cost of $12.83 per share, with a total value of $2,185,436.54. The transaction was disclosed in a filing with the SEC, which is available at this link.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Kala Pharmaceuticals (NASDAQ:KALA) Share Price” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Insider Buying and Selling by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply